Prazer Therapeutics Enters into Strategic Collaboration and License Agreement with Johnson & Johnson to Develop Novel Targeted Protein Degraders for Neurodegenerative Diseases Using SPiDEM ^® Technology

Seoul, South Korea – January 9, 2026 – Prazer Therapeutics Inc. (“Prazer” or the “Company”) today announced a strategic collaboration and license agreement with Johnson & Johnson* to advance the discovery of novel therapeutics for neurodegenerative diseases. The collaboration aims to leverage Prazer’s proprietary SPiDEM® (Selective Protein Degradation Enabling Moiety) platform technology to develop novel targeted protein degraders (TPD) for a neurodegeneration-relevant target.

"This collaboration represents another meaningful validation of Prazer’s SPiDEM® platform and its potential to advance targeted protein degradation to accelerate the discovery of potential new TPD medicines for patients," said Kyung-Soo Inn, Ph.D., Chief Executive Officer and Founder of Prazer.

This collaboration follows Prazer’s Series B financing led earlier this year by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.

* Legal entity: Janssen Pharmaceutica NV

About Prazer Therapeutics

Prazer is a private Korean biotech company developing orally available, brain-penetrant targeted protein degraders with a novel approach to targeted protein degradation (TPD). The Company’s proprietary SPiDEM™ platform is engineered to identify new degradation mechanisms and address limitations associated with traditional bivalent and monovalent protein degraders. Prazer is focused on advancing next-generation TPD therapeutics for a broad range of intractable diseases across neuroscience, oncology, and immunology. Prazer is a JLABS Korea member.

For more information, please visit https://prazertx.com/ and follow us on LinkedIn .

Prazer and SPiDEM^® are registered trademarks of Prazer Therapeutics Inc. in South Korea.